3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 4
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
163
Endometrial Neoplasms
13
Ovarian Neoplasms
12
Fallopian Tube Neoplasms
5
Recurrence
4
Neoplasms
4
Neoplasm Metastasis
4
Carcinoma, Intraductal, Noninfiltrating
4
Triple Negative Breast Neoplasms
3
Breast Diseases
3
Breast Cancer Metastatic
3
Prostatic Neoplasms
2
Leiomyosarcoma
2
Carcinoma, Lobular
2
Advanced Breast Cancer
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Polycystic Ovary Syndrome
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Pain
1
Osteoporosis
1
Neoplastic Cells, Circulating
1
Neoadjuvant Operable Breast Cancer
1
Multiple Endocrine Neoplasia Type 1
1
Medullary cystic kidney disease 1
1
Lymphangioleiomyomatosis
1
Interventions
Tamoxifen
10
Specimen Handling
5
Chemotherapy, Adjuvant
5
Radiotherapy
3
Mastectomy, Segmental
3
Anastrozole
3
Simvastatin
2
telapristone acetate
1
ruxolitinib
1
exemestane
1
abemaciclib
1
Vinorelbine
1
Trastuzumab
1
Telemedicine
1
Tablets
1
Surgical Procedures, Operative
1
Sugars
1
Starch
1
Soybean Proteins
1
Radiation Dose Hypofractionation
1
Radiation
1
Protons
1
Proton Therapy
1
Probiotics
1
Pharmacogenomic Testing
1
Omacor
1
Neoadjuvant Therapy
1
Naltrexone
1
Mastectomy, Subcutaneous
1
Lovastatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Breast Carcinoma In Situ
×
Letrozole
×
Clear all
NCT00090857
2018-03-30
WISE
Dana-Farber Cancer Institute
Phase 2
Completed
49 enrolled
17 charts